Literature DB >> 9124836

High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

C Janoir1, V Zeller, M D Kitzis, N J Moreau, L Gutmann.   

Abstract

The mechanism of high-level fluoroquinolone resistance was studied in strains of Streptococcus pneumoniae, either selected in vitro or isolated from clinical samples. By using DNA from these high-level-resistant strains, low-level-resistant transformants (MIC of pefloxacin, > or = 32 micrograms/ml; MIC of ciprofloxacin, 4 micrograms/ml; MIC of sparfloxacin, 0.50 micrograms/ml) were obtained at high frequencies (ca.10(-2)), while high-level-resistant transformants (MIC of pefloxacin, > or = 64 micrograms/ml; MIC of ciprofloxacin, 16 to 64 micrograms/ml; MIC of sparfloxacin, > or = 8 micrograms/ml) were obtained only at low frequencies (ca.10(-4)). This suggested that mutations in at least two unlinked genes were necessary to obtain high-level resistance. Low-level resistance was associated with ParC mutations (change from Ser to Tyr at position 79 [Ser79Tyr], Ser79Phe, or Asp83Gly). ParC mutations were associated, in high-level-resistant strains and transformants, with alterations in the quinolone resistance-determining region of GyrA (Ser84Tyr, Ser84Phe, and/or Glu88Lys). Low-level resistance was shown to be necessary for expression of the gyrA mutations. No mutation in the region corresponding to the quinolone resistance-determining region of GyrB and no alteration of drug accumulation were found.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124836      PMCID: PMC163617     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  In Vivo Selection of Streptococcus pneumoniae, Resistant to Quinolones, Including Sparfloxin.

Authors:  Louis Bernard; Jean-Claude Nguyen Van; Jean-Luc Mainardi
Journal:  Clin Microbiol Infect       Date:  1995-09       Impact factor: 8.067

2.  Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

Authors:  E Pérez-Trallero; J M Garcia-Arenzana; J A Jimenez; A Peris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

3.  In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.

Authors:  M A Cooper; J M Andrews; J P Ashby; R S Matthews; R Wise
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

4.  Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.

Authors:  S C Lafredo; B D Foleno; K P Fu
Journal:  Chemotherapy       Date:  1993       Impact factor: 2.544

5.  Marker discrimination in transformation and mutation of pneumococcus.

Authors:  J G Tiraby; M S Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

6.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

Review 7.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

8.  Quinolone-resistant mutations of the gyrA gene of Escherichia coli.

Authors:  H Yoshida; T Kojima; J Yamagishi; S Nakamura
Journal:  Mol Gen Genet       Date:  1988-01

9.  Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins.

Authors:  E E Margerrison; R Hopewell; L M Fisher
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  100 in total

1.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Authors:  C Janoir; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  Levofloxacin-resistant Streptococcus pneumoniae: second look.

Authors:  C Thornsberry; J A Karlowsky; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.

Authors:  D C Richardson; D Bast; A McGeer; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 6.  Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.

Authors:  S J Schrag; B Beall; S F Dowell
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

7.  Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

8.  In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

Authors:  T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

9.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

10.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.